找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Breast Cancer Treatment: An Interdisciplinary Approach; Nima Rezaei Book 2024 The Editor(s) (if applicable) and The Author(s), under exclu

[復(fù)制鏈接]
樓主: 淹沒
51#
發(fā)表于 2025-3-30 12:10:12 | 只看該作者
Claudin 1: An Emerging Target for Triple-Negative Breast Cancer, to treat these tumors lacking efficient therapies. Clinical studies reported that a loss of claudin 1 expression correlates with increased aggressiveness and metastasis potential associated with recurrence of disease in invasive breast carcinoma patients. Although the role of claudin 1 in breast ca
52#
發(fā)表于 2025-3-30 14:29:41 | 只看該作者
53#
發(fā)表于 2025-3-30 16:52:57 | 只看該作者
54#
發(fā)表于 2025-3-30 22:37:18 | 只看該作者
55#
發(fā)表于 2025-3-31 01:28:35 | 只看該作者
56#
發(fā)表于 2025-3-31 08:20:30 | 只看該作者
57#
發(fā)表于 2025-3-31 11:51:39 | 只看該作者
https://doi.org/10.1007/978-3-658-34614-0tment plan. The dose of radiation given is split into fractions, usually given daily, over a few days or weeks, depending on the choice of radiotherapy. A combination of chemotherapy or immunotherapy with radiotherapy is recommended for the progressive stages of breast cancer. This chapter dwells on
58#
發(fā)表于 2025-3-31 14:28:03 | 只看該作者
59#
發(fā)表于 2025-3-31 19:20:50 | 只看該作者
Reproduzierbarkeit verteilter Simulation,d low-risk DCIS patients. However, apart from oncologic outcomes, the patient’s acceptance and the psychosocial impact of conservative treatment for DCIS should be taken into consideration in the treatment planning for DCIS..The importance of oncologic safety is obvious in decision-making, but to pa
60#
發(fā)表于 2025-4-1 00:03:11 | 只看該作者
Methoden wissensbasierter Systeme retrospective 2:1 ratio control-case study where ER+ breast cancer patients who benefited clinically during conventional first-line antiestrogen HT additionally received cyclic interferon beta interleukin-2 sequence, showed superior results to those who received HT alone, and results also were comp
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-6 17:47
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
峡江县| 凤翔县| 金华市| 梨树县| 昌乐县| 德昌县| 辽阳县| 怀集县| 民勤县| 乐都县| 苏尼特左旗| 陵川县| 高安市| 抚州市| 长乐市| 大埔县| 双鸭山市| 秭归县| 理塘县| 绥德县| 乐都县| 太白县| 庆云县| 建湖县| 保定市| 西畴县| 洛宁县| 甘泉县| 项城市| 三河市| 威远县| 平邑县| 青河县| 长春市| 泾阳县| 手游| 肥乡县| 额济纳旗| 莱芜市| 中山市| 兴业县|